השוואת שיטות

	איכות חיים באפילפסיה-89 (QOLIE-89)	סולם רנקין מותאם (mRS)	סולם איכות חיים ספציפי לשבץ מוחי (SS-QoL)
תחום	נוירולוגיה	נוירולוגיה	נוירולוגיה
משפחה	Process / pipeline	Process / pipeline	Process / pipeline
שנת המקור	1995	1988	1999
הוגה השיטה	Orrin Devinsky, NYU	Rankin scale original (Rankin, 1957); modified version by van Swieten et al.	Lee S. Williams, Indiana University
סוג	Self-report questionnaire	Clinician-rated ordinal scale	Self-report questionnaire
מקור מכונן	Devinsky, O., Vickrey, B. G., Cramer, J., Edwards, B., Perrine, K., Hamberger, M. J., & Towle, V. L. (1995). Development of the Quality of Life in Epilepsy Inventory. Epilepsia, 36(11), 1089-1104.	van Swieten, J. C., Koudstaal, P. J., Visser, M. C., Schouten, H. J., & van Gijn, J. (1988). Interobserver agreement for the assessment of handicap in stroke patients. Stroke, 19(5), 604-607.	Williams, L. S., Weinberger, M., Harris, L. E., Clark, D. O., & Biller, J. (1999). Development of a Stroke-Specific Quality of Life Scale. Stroke, 30(7), 1362-1369.
כינויים	QoLIE-89	mRS, Rankin Scale, Modified Rankin	Stroke-Specific QoL, SS-QOL
קשורות	3	4	4
תקציר	The QOLIE-89 is a comprehensive disease-specific quality-of-life instrument developed specifically for people with epilepsy. Introduced by Devinsky and colleagues in 1995, it captures the broad impact of epilepsy on physical, emotional, social, and cognitive functioning. With 89 items organized into 17 distinct domains, it remains one of the most detailed QoL assessments for epilepsy and is widely used in clinical trials, health services research, and outcome monitoring.	The Modified Rankin Scale is a simple 0-6 ordinal measure of global disability or dependency in patients with stroke and other neurological conditions. Originally developed by Rankin in 1957 and modified by van Swieten and colleagues in 1988, it remains the most widely used global disability outcome in stroke clinical trials and clinical practice. Its simplicity, brevity, and strong prognostic association make it the gold standard for acute stroke outcome measurement and is mandated as a primary endpoint in virtually all stroke therapeutic trials.	The SS-QoL is a disease-specific quality-of-life instrument designed to capture the multidimensional impact of stroke on survivors' functional and emotional well-being. Developed by Williams and colleagues in 1999, this 49-item scale addresses stroke-specific concerns including language, cognition, mobility, and emotional functioning. It is a gold-standard instrument for stroke outcome research and routine clinical monitoring of post-stroke recovery.